Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 13/20 | 0.53 |
| ▸ | NPY1R | P25929 | 8/20 | 0.53 |
| ▸ | NPY2R | P49146 | 6/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22117536 | 1.00 | NPY4R (0.53) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL22117549 | 1.00 | NPY4R (0.53) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL22117809 | 0.97 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL22117807 | 0.97 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL22117584 | 0.93 | NPY4R (0.53) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL22117582 | 0.93 | NPY4R (0.53) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL22117401 | 0.93 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL22117402 | 0.93 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL22117476 | 0.90 | NPY4R (0.47) | NPY4RNPY1RNPY2RNPY5ROPRM1 | |
| SCHEMBL22117482 | 0.90 | NPY4R (0.47) | NPY4RNPY1RNPY2RNPY5ROPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404300-B2 | Mitochondria-targeting peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-09-02 | — | — | US | disclosed |
| CN-113544138-B | Mitochondrial targeting peptides | 隐形生物治疗公司 | 2024-10-29 | — | — | CN | disclosed |
| EP-3898652-A1 | MITOCHONDRIA-TARGETING PEPTIDES | Stealth Biotherapeutics Corp (MC) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020131282-A1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS CORP. (MC) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020131282-A1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS CORP. (MC) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404300-B2 | Mitochondria-targeting peptides | SSBP1, HSPE1, IMMT | NPY4R 2540/4885NPY1R 2382/4885NPY2R 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.